Products Trastuzumab is commercially available as a lyophilizate for preparation of an infusion concentrate (Herceptin, biosimilars). It has been approved in many countries since 1999 (US: 1998, EU: 2000). In 2016, an additional solution for subcutaneous injection for breast cancer therapy was released in many countries (Herceptin subcutaneous). It was available earlier in other countries. … Trastuzumab
Products Elotuzumab was approved in the United States in 2015 and in the EU and Switzerland in 2016 as a powder for the preparation of an infusion solution (Empliciti). Structure and properties Elotuzumab is a humanized IgG1 monoclonal antibody with a molecular weight of 148.1 kDa. It is produced by biotechnological methods. Effects Elotuzumab (ATC … Elotuzumab
Products Busulfan is commercially available as a concentrate for the preparation of an infusion solution (Busilvex). It has been approved in many countries since 2004. Structure and properties Busulfan (C6H14O6S2, Mr = 246.3 g/mol) exists as a white crystalline powder that is very sparingly soluble in water. Effects Busulfan (ATC L01AB01) has cytotoxic properties. Indications … Busulfan
Products Daratumumab was approved as an infusion product in the United States in 2015 and in many countries and the EU in 2016 (Darzalex). Structure and properties Daratumumab is a humanized IgG1κ monoclonal antibody with a molecular mass of approximately 148 kDa. It is produced by biotechnological methods. Effects Daratumumab (ATC L01XC24) has antitumor and … Daratumumab
Products Gefitinib is commercially available in the form of film-coated tablets (Iressa). It was approved in many countries in 2011. Structure Gefitinib (C22H24ClFN4O3, Mr = 446.9 g/mol) is a morpholine and aniline quinazoline derivative. It exists as a white powder that is sparingly soluble in water, especially at high pH. Effects Gefitinib (ATC L01XE02) is … Gefitinib
Products Ondansetron is commercially available in the form of film-coated tablets, meltable tablets (lingual tablets), as a syrup, and as an infusion/injection preparation. In addition to the original Zofran, generic versions are also available. Ondansetron was introduced in 1991 as the first active ingredient from the group of 5-HT3 receptor antagonists was approved. Structure and … Ondansetron
Products Cabazitaxel is released as a concentrate for the preparation of an infusion solution. It has been approved in many countries since 2011 (Jevtana). Structure and properties Cabazitaxel (C45H57NO14, Mr = 835.9 g/mol) is a taxane semisynthetically derived from a constituent of yew needles. It is structurally closely related to docetaxel, which is itself a … Cabazitaxel
Products Calcipotriol is commercially available as a fixed combination with betamethasone dipropionate as a gel, ointment, and foam (Xamiol, Daivobet, Enstilar, generics). Structure and properties Calcipotriol (C27H40O3, Mr = 412.60 g/mol) is a synthetic derivative of natural vitamin D3 (cholecalciferol). It exists as a white crystalline powder. Effects Calcipotriol (ATC D05AX02) has antiproliferative, anti-inflammatory, and … Calcipotriol
Products Capecitabine is commercially available in the form of film-coated tablets (Xeloda, generic). It has been approved in many countries since 1998. Structure and properties Capecitabine (C15H22FN3O6, Mr = 359.4 g/mol) is a prodrug and is converted to the cell-toxic 5-fluorouracil, the active drug, in a three-step process. Capecitabine exists as a white crystalline powder … Capecitabine
Products Pegaspargase is commercially available as an injectable (Oncaspar). The drug was approved in the United States in 2006, in the EU in 2016, and in many countries in 2017. Structure and properties Pegaspargase (PEG-L-asparaginase) is the pegylated enzyme L-asparaginase. The PEG units are covalently attached to the enzyme. Effects Pegaspargase (ATC L01XX24) has antileukemic … Pegaspargases
Products Pegfilgrastim is commercially available as a solution for injection in the form of prefilled syringes (Neulasta). It has been approved in many countries since 2003. Biosimilars have been approved. Structure and properties Pegfilgrastim is a conjugate of filgrastim with a single 20-kDa polyethylene glycol (PEG) molecule. Filgrastim is a protein of 175 amino acids … Pegfilgrastim
Products Blinatumomab is commercially available as an infusion product (Blincyto). It has been approved in the United States since 2014, in the EU since 2015, and in many countries since 2016. Structure and properties Blinatumomab is an antibody construct (fusion protein) of 504 amino acids with a molecular weight of approximately 54 kDa. It consists … Blinatumomab
